AML
- Zhang H, Savage S, Schultz AR, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications 2019; 10(1): 244.
- Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. Nature 2018; 562(7728): 526-31.
- Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors. Leukemia 2015; 29(12): 2390-2.
- Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a Potent Inhibitor of FLT3 with Activity Against Resistance-Conferring Point Mutants. Blood 2014; 123(1): 94-100.
- Zhang W, Gao C, Konopleva M, et al. Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies. Clin Cancer Res 2014; 20(9): 2363-74.
- Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a Selective Type I Pan-FLT3 Inhibitor. Proc Natl Acad Sci U S A 2014; 111(14): 5319-24.
- Fathi AT. Emergence of Crenolanib for FLT3-Mutant AML. Blood 2013; 122(22): 3547-8.
- Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is Active Against Models of Drug-Resistant FLT3-ITD-Positive Acute Myeloid Leukemia. Blood 2013; 122(22): 3607-15.
GIST
- Blay J-Y, Heinrich MC, Hohenberger P, et al. A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: The CrenoGIST study. J Clin Oncol 2017; 35 (suppl; abstr TPS11080).
- von Mehren M, Tetzlaff ED, Macaraeg M, et al. Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. J Clin Oncol 2016; 34 (suppl; abstr 11010).
- Matro JM, Yu JQ, Heinrich MC, Ramachandran A, Ku N, Mehren Mv. Correlation of PET/CT and CT RECIST response in GIST patients with PDGFRA D842V gene mutations treated with crenolanib. J Clin Oncol 2014; 32:5s (suppl; abstr 10546).
- Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012; 18(16): 4375-84.
- Michael M, Vlahovic G, Khamly K, Pierce KJ, Guo F, Olszanski AJ. Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. Br J Cancer 2010; 103(10): 1554-61.
- Lewis NL, Lewis LD, Eder JP, et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol 2009; 27(31): 5262-9.